


Please type  
plus sign (+)  
in this box



Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	10/036,768
	<b>Filing Date</b>	November 6, 2001
	<b>First Named Inventor</b>	Fast
	<b>Group Art Unit</b>	1617
	<b>Examiner Name</b>	Jennifer Kim
	<b>Attorney Docket Number</b>	18242-511 (VI-0008-P3)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
<input checked="" type="checkbox"/>	C1	Richter et al. (1998). "Extracorporeal photopheresis in therapy-refractory disseminated discoid lupus erythematosus!" <i>Hautarzt</i> 49(6): 487-491.
<input checked="" type="checkbox"/>	C2	Chapman (2000). "Progress in improving the pathogen safety of red cell concentrates" <i>Vox Sang</i> 78(2): 203-204.
<input checked="" type="checkbox"/>	C3	Fast et al. (2000). "Treatment of human leukocytes with inactine™ results in loss of function and induction of apoptosis" <i>Blood</i> 96(11): 61A
<input checked="" type="checkbox"/>	C4	Lobastov, A.E., (1983) "Use of ethylenimine dimer for the inactivation of infectious rhinotracheitis virus of cattle" <i>Probl. Virusol., Mol. Biol. Gistol. S-kh Zhivotn.</i> , 4-6.
<input checked="" type="checkbox"/>	C5	<del>Amor, S. and H.E. Webb, "Use of N-Acetylnethylamine [AEI] for the activation of Semliki Forest Virus in vitro" <i>J. Medical Virology</i> 19:367-376.</del> no date
<input checked="" type="checkbox"/>	C6	Zalesskaya, M.A., "Inactivation of viral genome by beta-propiolactone and ethyleneimines using the bacteriophage MA-2 as an example", Russian State Library, Moscow, Russia (1991)
<input checked="" type="checkbox"/>	C7	<del>Budowsky, E.I., "Problems and prospects for preparation of killed antiviral vaccines" <i>Ad. Virus Res.</i> 30:255-30</del> no date
<input checked="" type="checkbox"/>	C8	<del>Hassanain, M.M., "Preliminary findings for an inactivated African horsesickness vaccine using binary ethylenimine" <i>Revue Elev. Med. Vet. Pays Trop.</i> 45:231-234</del> no date
<input checked="" type="checkbox"/>	C9	<del>Russian Patent: SU 1809836 A3</del> no date
<input checked="" type="checkbox"/>	C10	Budowsky, et al. "Inactivation of the phage MS2 Infectivity by the Action of Ethyleneimines" <i>Biorg. Khim.</i> 11:989-991 (1985)
<input checked="" type="checkbox"/>	C11	<del>Budowsky, et al. "Principles of selective inactivation of the viral genome; dependence of the rate of viral RNA modification on the number of protonizable groups on ethyleneimine Oligomers" <i>Vaccine Res.</i> 5:29-39</del> no date
<input checked="" type="checkbox"/>	C12	Abstract No. S137-040, AABB Meeting, held in San Antonio, TX, Oct. 13-17, 2001 "Pen 110 Treatment is More Effective than Conventional Gamma Irradiation at Inhibiting Human Peripheral Blood Mononuclear Cell Function: In Vitro Studies".
<input checked="" type="checkbox"/>	C13	Abstract No. SP 185, AABB Meeting, held in San Antonio, TX, Oct. 13-17, 2001 "Removal of White Blood Cell and Plasma Proteins from Leukofiltered Red Blood Cell Concentrates by INACTINE™ Pathogen Inactivation"
<input checked="" type="checkbox"/>	C14	Seghatchian, M.J. et al. Abstract: "Transfusion-associated graft-versus-host disease: current concepts and future trends" <i>Transfus Sci</i> 1995, Jun; 16(2): 99-105.
<input checked="" type="checkbox"/>	C15	Fast, L.D. Abstract: "Recipient CD8+ cells are responsible for the rapid elimination of allogeneic donor lymphoid cells" <i>J Immunol</i> 1996 Dec 1; 157(11):4805-10.
<input checked="" type="checkbox"/>	C16	Fast, L.D. et al. Abstract: "Immune responses to major histocompatibility complex homozygous lymphoid cells in murine F1 hybrid recipients: implications for transfusion-associated graft-versus-host disease" <i>Blood</i> 1995 Oct 15;86(8):3090-6.



OTHER PRIOR ART PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
7	C17	Fast, L.D. "In Vitro Characterization of a Murine Recipient Anti-Donor Effector Cell Responsible for the Development of Chronic Graft-Versus-Host Disease" <i>The Journal of Immunology</i> , Vol. 147, 1731-38, September 15, 1991.
	C18	Fast, L.D. "Recipient Elimination of Allogeneic Lymphoid Cells: donor CD4+ cells are effective alloantigen-presenting cells" <i>Blood</i> , 1 Aug 2000, pp 1144-49, Vol. 96, No. 3.
	C19	Grass, J.A. et al. "Prevention of transfusion-associated graft-versus-host disease by photochemical treatment" <i>Blood</i> 1999 May 1; 93(9):3140-7.
	C20	Yasuda, H et al. Abstract: Mechanism of Transfusion-associated graft-versus host disease" <i>Fukushima J. Med. Sci</i> 1993 Dec; 39(2): 69-75.
	C21	Tsvetkova, E.A. et al. "Principles of Selective Inactivation of a Viral Genome. Comparative Kinetic Study of Modification of the Vira RNA and Model Protein with Oligoaziridines" <i>Biochemistry (Moscow)</i> , Vol. 66. No. 8 pp. 875-884. Translated from <i>Biokhimiya</i> , Vol. 66 No. 8, 2001 pp. 1078-1088.
	C22	Kasermann, F. et al. "Virus Inactivation and Protein Modifications by Ethyleneimines" <i>Antiviral Research</i> 52 (2001) pp. 33-41.
7	C23	International Search Report for PCT/US 01/49956. Mailed on July 23, 2002.

\* A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	4/27/04
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.